Remove Pharma R&D Remove Production Remove Small Molecule Remove Trials
article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

No surrogate marker (selecting a development candidate, starting human trials, or (arguably) even launching a drug are reliable indicators of the only things that matter: real-world clinical utility and commercial success. Want to know if your AI-identified tweaks to the productivity of your chemical plant do indeed improve output?

article thumbnail

Rethinking the pharma R&D lifecycle with AI in mind

Drug Discovery World

Large pharma companies now spend more than $6 billion 4 on R&D per approved drug, compared to just $40 million 5 (in today’s dollars) in the 1950s, with approximately 85% of that spending coming after discovery. Take as an example patient recruitment, the most time-consuming part of a trial.